Immunocore to present at upcoming investor conferences
04 April 2024 - 10:00PM
Immunocore to present at upcoming
investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc
(Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage
biotechnology company pioneering and delivering transformative
immunomodulating medicines to radically improve outcomes for
patients with cancer, infectious diseases and autoimmune diseases,
today announced that management will participate in the following
investor conferences in April:
- Needham Virtual Healthcare
Conference Fireside Chat: Wednesday, April 10, 2024, at
11:00 a.m. EDT
- Canaccord Horizons in
Oncology Panel: T-Cell Engagers for Solid Tumors: Monday,
April 15, 2024, at 4:00 p.m. EDT
- Kempen Life Sciences
Conference1x1 and small group meetings: Tuesday, April 16,
2024
Where relevant, the presentations will be
webcast live and can be accessed by visiting ‘Events’, under ‘News
& Events’, via the ‘Investors’ section of Immunocore’s website
at www.immunocore.com. Following the event, a replay of the
presentations will be made available for a limited time.
About
Immunocore Immunocore is a commercial-stage
biotechnology company pioneering the development of a novel class
of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including five clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK
(tebentafusp) has been approved for the treatment of
HLA-A*02:01-positive adult patients with unresectable or metastatic
uveal melanoma in the United States, European Union, Canada,
Australia, and the United Kingdom.
CONTACT: Immunocore Sébastien
Desprez, Head of Communications T: +44 (0) 7458030732 E:
mailto:sebastien.desprez@immunocore.com Follow
on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor Relations T: +1 215-384-4781 E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
